BMO Capital analyst Keith Bachman maintains Splunk (NASDAQ:SPLK) with a Outperform and lowers the price target from $120 to $100.
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $52
JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $37 to $52.